All In Biotech

Drug Trial Radar · NCT06822907

Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults

Immunogenicity and Safety of the 20-Valent Pneumococcal Conjugate Vaccine (PCV-20) Administered During an Acute Febrile Illness in Adults: a Multicentric Randomized Non-inferiority Trial

Last checked: Nov 20, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,052 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,052

Planned (sponsor's estimate)

Start

Dec 17, 2025

Primary completion

Oct 1, 2028

Study completion Oct 1, 2028

Sponsor

Lead sponsor
Centre Hospitalier Universitaire de Saint EtienneAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Health, France; IREIVAC/COVIREIVAC Network
First posted
Feb 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Streptococcus pneumoniae is responsible for serious infections associated to numerous hospitalizations and high rate of mortality. The incidence and therefore the burden of pneumococcal infections have been significantly reduced thanks to the use of pneumococcal conjugate vaccines (PCVs). PCVs were shown to be effective against vaccine-type serotypes causing both non-invasive and invasive pneumococcal diseases (IPD) in children and adults. PCVs use in children was shown to have an impact on IPD incidence among adults due to herd immunity and on antimicrobial resistance. To increase the protection of at-risk patients against IPD, the 20-valent PCV (PCV-20) is recently recommended in adults, after a period where PCV-13 followed by pneumococcal polysaccharide vaccine 23 valent (PPV-23) was recommended. PCV-20 effectiveness against IPD and against pneumonia was inferred from immunobridging with PCV-13. Indeed PCV-13 was shown effective to reduce the incidence of low respiratory tract infections and IPD (bacteraemia and meningitis) in 65-years-old-adults and older. Currently immunization against S. pneumoniae is recommended with PCV-20 for adult patients at-risk for IPD such as immunocompromised (=high-risk patients) and in immunocompetent people with underlying chronic conditions (cardiovascular, liver, pulmonary, kidney diseases and diabetes mellitus) (=medium risk patients). However, vaccine coverage against IPD in adults remains low globally, and does not exceed 5 % in France. Reducing missed opportunities of vaccination for S. pneumoniae is crucial.

Conditions

  • Acute Febrile Illness
  • Pneumococcal Infections

Interventions

  • Early interventionBiological

    In this arm, patient will receive unique dose of the PCV-20 vaccine (Prevnar 20) as soon as possible and until 72h after apyrexia. The "Prevenar 20" will be used Prevenar 20 will be injected by intramuscular route. The preferred site of injection is the deltoid muscle of the upper arm in adults.

  • Delayed interventionBiological

    In this arm, from 15 days and until 58 days after fever resolution (i.e after the first day with a body temperature \< 37.5°C without paracetamol use in the 6 previous hours) (whether or not the patient has been discharged) in the absence of fever, the patient will receive unique dose of the PCV-20 vaccine (Prevnar 20). The "Prevenar 20" will be used Prevenar 20 will be injected by intramuscular route. The preferred site of injection is the deltoid muscle of the upper arm in adults.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of immune "good responders" to PCV-20 in both armsTime frame: 1 month post vaccination

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Centre Hospitalier

    Annecy, France · Not yet recruiting

  • Centre Hospitalier Universitaire

    Besançon, France · Not yet recruiting

  • Centre Hospitalier

    Bordeaux, France · Not yet recruiting

  • Centre Hospitalier Universitaire

    Brest, France · Not yet recruiting

  • Centre Hospitalier

    Brest, France · Not yet recruiting

  • Centre Hospitalier General Metropole Savoie

    Chambéry, France · Not yet recruiting

  • Centre Hospitalier de Creteil

    Créteil, France · Not yet recruiting

  • Centre Hospitalier Universitaire

    Dijon, France · Not yet recruiting

  • Centre Hospitalier Universitaire

    Grenoble, France · Not yet recruiting

  • Centre Hospitalier

    La Roche-sur-Yon, France · Not yet recruiting

  • Centre Hospitalier General

    Le Mans, France · Not yet recruiting

  • Centre Hospitalier

    Le Puy-en-Velay, France · Not yet recruiting

  • Centre Hospitalier Universitaire

    Lille, France · Not yet recruiting

  • Hospices Civils de Lyon

    Lyon, France · Not yet recruiting

  • Centre Hospitalier Regional Universitaire

    Montpellier, France · Not yet recruiting

  • Centre Hospitalier Universitaire

    Nancy, France · Not yet recruiting

  • Centre Hospitalier Universitaire

    Nantes, France · Not yet recruiting

  • Centre Hospitalier Universitaire

    Nice, France · Not yet recruiting

  • Centre Hospitalier Universitaire

    Nîmes, France · Not yet recruiting

  • Centre Hospitalier Bichat

    Paris, France · Not yet recruiting

  • Assistance Publique Hopitaux de Paris

    Paris, France · Not yet recruiting

  • Centre Hospitalier Universitaire

    Rennes, France · Not yet recruiting

  • Centre Hospitalier Universitaire

    Rouen, France · Not yet recruiting

  • CHU de Saint-Etienne

    Saint-Etienne, France, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.